Shirdi Pharmaceutical Consultancy Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 27-06-2024
- Paid Up Capital ₹ 0.10 M
as on 27-06-2024
- Company Age 11 Year, 7 Months
- Last Filing with ROC 31 Mar 2019
- Revenue -97.72%
(FY 2019)
- Profit -496.02%
(FY 2019)
- Ebitda -257.82%
(FY 2019)
- Net Worth -89.09%
(FY 2019)
- Total Assets -89.68%
(FY 2019)
About Shirdi Pharmaceutical Consultancy
The Company is engaged in the Business Outsourcing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Parwathamma, Appanna Jayamma, Narasimha Murthy, and Four other members serve as directors at the Company.
- CIN/LLPIN
U85110KA2013PTC069267
- Company No.
069267
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 May 2013
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Shirdi Pharmaceutical Consultancy?
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ganesh Bhat  | Director | 23-May-2013 | Current |
| Parwathamma | Director | 11-Aug-2014 | Current |
| Appanna Jayamma | Director | 11-Aug-2014 | Current |
| Narasimha Murthy | Director | 11-Aug-2014 | Current |
| Kattimane Virupakshappa | Director | 13-Jan-2014 | Current |
| Yeraguntlu Eswaramma | Director | 13-Jan-2014 | Current |
Financial Performance of Shirdi Pharmaceutical Consultancy.
Shirdi Pharmaceutical Consultancy Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 97.72% decrease. The company also saw a substantial fall in profitability, with a 496.02% decrease in profit. The company's net worth observed a substantial decline by a decrease of 89.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shirdi Pharmaceutical Consultancy?
In 2019, Shirdi Pharmaceutical Consultancy had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nedfharm Consultancy Private LimitedActive 6 years 3 monthsYeraguntlu Eswaramma and Ganesh Bhat are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Shirdi Pharmaceutical Consultancy?
Unlock and access historical data on people associated with Shirdi Pharmaceutical Consultancy, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shirdi Pharmaceutical Consultancy, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shirdi Pharmaceutical Consultancy's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
